On the basis of the protocol definition, three patients experienced treatment failure during the 24-wk follow-up period: two control participants (one commenced antiretroviral therapy at week 16 after being diagnosed with nonvisceral Kaposi's sarcoma and one had a decreased CD4 count); and one participant assigned 7.5 MIU IL-2 (who commenced antiretroviral therapy at week 24 after being diagnosed with visceral Kaposi's sarcoma). This evidence concerns the gene IL2 and Kaposi's sarcoma.